MAR002

Sept. 17, 2026: Lisata Therapeutics (NASDAQ: LSTA) announced the acquisition of Marea Therapeutics and a concurrent $225 million private placement financing. The combined company will focus on Marea’s cardioendocrine pipeline, with proceeds expected to fund operations into 2028.

MAR001/005: MAR001 is in an ongoing Phase 2b trial for severe hypertriglyceridemia (sHTG), and MAR005 is described as a half-life-extended version planned as the Phase 3 candidate. Lisata said the Phase 2b study is expected to report topline data in Q4 2027, and the company cited plans to initiate Phase 3 registrational studies.

MAR002: MAR002, for acromegaly, is advancing into or being evaluated in a Phase 2 trial. The company said Phase 2 proof-of-concept/topline data are expected in Q4 2027. The release states that in a Phase 1 study in healthy volunteers, MAR002 produced dose-dependent IGF-1 suppression, was generally well tolerated, and had no serious adverse events.

Transaction details: Marea shareholders received Lisata common stock and Series C non-voting convertible preferred stock; pre-transaction Lisata holders will own about 2.39% of the company, former Marea holders about 59.54%, and financing investors about 38.07% on an as-converted basis. Lisata stockholder approval is still required for conversion of the Series C preferred shares into common stock.